Clinical Trials Logo

Acceptability of Mass Drug Administration for Lymphatic Filariasis clinical trials

View clinical trials related to Acceptability of Mass Drug Administration for Lymphatic Filariasis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04124250 Recruiting - Clinical trials for Lymphatic Filariasis Elimination by Mass Drug Administration

East New Britain Province Monitoring & Evaluation

ENBP M&E
Start date: September 17, 2019
Phase:
Study type: Observational

While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020 will be achieved. As of 2016, it was estimated that 856 million people are still living in areas with ongoing transmission of LF and require mass drug administration (MDA) [1]. Of the 52 countries that remain endemic and require MDA, 22 (42%) have not started MDA in all endemic implementation units (IUs) [1]. In addition, several countries have found that, despite completing the required number of treatment rounds, the response to the present MDA regimen has been suboptimal in some IUs, requiring additional rounds of MDA.